Earlier in 2016 Willis-Knighton Health System purchased two Elekta Versa HD linear accelerators as part of the Willis-Knighton Cancer Center’s continuing technology upgrades. The first of the accelerators has been installed, and patients are currently being treated using this advanced linear accelerator technology.
Willis-Knighton Cancer Center will recognize cancer survivors on National Cancer Survivors Day Sunday, June 5, from 1 to 3 p.m. at the center, 2600 Kings Highway in Shreveport.
Willis-Knighton Cancer Center is now offering Optune, a medical device that, when used in conjunction with partial-brain radiotherapy and chemotherapy, has been shown to extend overall survival and progression-free survival of newly diagnosed patients with glioblastoma multiforme (GBM). Optune is a portable, noninvasive device that delivers low-intensity, alternating electric fields (referred to as Tumor Treating Fields) that inhibit cancer cell replication and cause cancer cells to die.
Patients at Willis-Knighton Cancer Center can be confident about the quality of their case as the Willis-Knighton Cancer Center exceeds both state and national standards.
In January Willis-Knighton Cancer Center joins leading cancer centers in the United States in a new research initiative evaluating two types of radiation therapy approved by the U.S. Food & Drug Administration for the treatment of breast cancer.
The Willis-Knighton Cancer Center has added cone beam computed tomography (CBCT) to its ProteusONE compact proton therapy solution. This is the first FDA approved CBCT for compact proton therapy to be used for treatment of a breast cancer patient.
Four physicians from the Willis-Knighton Physician Network are scheduled to serve as panelists for a free seminar targeted to survivors of gynecologic cancer and their family and friends. The event is scheduled June 27 from 8 a.m. to 2 p.m. at the Hilton Shreveport Hotel in downtown Shreveport and is being presented by the Foundation for Women’s Cancer.
Willis-Knighton Health System has announced that its Proton Therapy Center at the Willis-Knighton Cancer Center has begun treating patients with advanced pencil beam proton therapy.
The proton beam was tuned by a team of physicists and engineers led by IBA’s founder and chief research officer, Yves Jongen. The beam reached target specifications for beam size and shape at isocenter (where the patient will be treated).
The Willis-Knighton Cancer Center is hosting a proton therapy physics workshop in Shreveport on Friday and Saturday, Nov. 22 and 23, featuring local, national and international speakers. More than 70 physicists, dosimetrists and others interested in radiation physics will participate.
Willis-Knighton Cancer Center’s Department of Radiation Oncology is being represented this week at the annual world conference of the American Society of Radiation Oncology (ASTRO). ASTRO’s annual meeting is touted as the premier radiation oncology scientific event in the world and draws more than 11,000 to hear presentations.
Jarron Syh has been announced as the first graduate of the Willis-Knighton Cancer Center’s medical physics residency program.
Willis-Knighton Health System announces a major step in the development of the WK Proton Therapy Center, the arrival of the cyclotron as part of the ProteusONE™ with pencil beam scanning technology.
The Willis-Knighton Cancer Center and Willis-Knighton Health System are joining with the American Cancer Society and other local organizations to promote and support a study that has the potential to change the face of cancer. Local residents are being recruited to participate in the American Cancer Society’s Cancer Prevention Study-3 (CPS-3) which will give scientists a better understanding of cancer causes and prevention.
Lane R. Rosen, M.D., medical director of radiation oncology at the Willis-Knighton Cancer Center, spoke to the American Association of Physicists in Medicine (AAPM) at their meeting in New Orleans on Saturday, Feb. 16.
The Willis-Knighton Cancer Center has completed a study of patients diagnosed with breast cancer who had lymph node involvement on a sentinel lymph node biopsy.
Lane R. Rosen, M.D., medical director of radiation oncology at the Willis-Knighton Cancer Center, will be presenting at the American Society for Radiation Oncology (ASTRO) 54th annual meeting in Boston next week.
Lane Rosen, M.D., medical director of radiation oncology Willis-Knighton Cancer Center, presented research on lung cancer treated with radiosurgery or SBRT at the Multidisciplinary Symposium in Thoracic Oncology in Chicago earlier this month.
Expanding by 53,000 square feet, Willis-Knighton will be among the first in the world to provide a new type of radiation therapy.
Dr. Lane Rosen, medical director of radiation oncology at Willis-Knighton Cancer Center, will appear in a 90-second segment during the FOX Primetime special “Stand Up To Cancer.” The telethon airs locally on KMSS FOX 33 on Sept. 7 at 7 p.m.
Willlis-Knighton Cancer Center’s medical physics residency program, established by the medical physicists and radiation oncologists at the Willis-Knighton Cancer Center, has received a five-year accreditation from the Commission on Accreditation of Medical Physics Educational Programs (CAMPEP).The report from CAMPEP indicated the program should be a model for centers seeking accreditation.
Willis-Knighton Cancer Center medical physics resident Jarron Syh presented three posters at the American Association of Physicists in Medicine (AAPM) annual meeting in Charlotte, N.C., earlier this month.
Joyce E. Feagin, M.D., with Hematology/Oncology Associates, will be featured on NBC’s Today Show on Thursday, Jan. 12. All this week, the Today Show is celebrating the show’s 60th Anniversary. As part of the anniversary celebration, Today Show producers asked viewers to submit stories about being loyal to Today. Her husband Gerald submitted her story.
The Commission on Cancer (CoC) of the American College of Surgeons has granted its Outstanding Achievement Award to Willis-Knighton Cancer Center as a result of surveys performed during 2010. Willis-Knighton Cancer Center is one of a select group of 90 currently accredited and newly accredited cancer programs across the United States.
The Commission on Cancer (CoC) of the American College of Surgeons has awarded a three-year accreditation with commendation to Willis-Knighton Cancer Center. This accreditation is granted when a program complies with all standards and receives a commendation rating.
Lane R. Rosen, M.D., director of radiation oncology at the Willis-Knighton Cancer Center, was named as the American College of Radiology (ACR) resource to the “H-34 Task Force on Helical IMRT” of the Conference of Radiation Control Program Directors (CRCPD).
Robin A. Lacour, M.D., M.P.H., has joined Destin Black, M.D. at Gynecologic Oncology Associates. The office is located in Suite 420 of the Willis-Knighton Cancer Center, 2600 Kings Highway in Shreveport.
Christopher M. Wilson, M.D., has joined W. Stewart Bundrick, M.D., and Elizabeth Harrel, M.D., at Ark-La-Tex Urology and Prostate Cancer Institute.
Willis-Knighton and the Captains hope to increase awareness to head & neck cancer which is directly attributed to the use of tobacco products including smokeless tobacco. The event also honors the memory of Jason Bland, certified athletic trainer with Willis-Knighton Sports Medicine and Airline High School, who died from head and neck cancer on June 7.
Michael R. Moore, M.D., F.A.C.P., hematologist / oncologist at the Willis-Knighton Cancer Center, has returned from New Orleans where he presented the results of a phase II study at the Poster Session of the American Society of Hematology Meeting. The study was entitled "Efficacy and Safety of Romiplostim in Patients with Low- or Intermediate-Risk Myelodysplastic Syndtome (MDS) Receiving Decitibine."
Willis-Knighton has announced plans to construct Louisiana’s first hospital-based proton beam therapy center adjacent to the Willis-Knighton Cancer Center, setting the stage for cancer patients in the region to have access to this revolutionary technology. This project represents an investment of approximately $30 million in technology, construction and design.